MARKET

SABSW

SABSW

SAB BIOTHERAPEUTICS INC
NASDAQ
0.0389
+0.0009
+2.37%
Closed 14:12 01/07 EST
OPEN
0.0385
PREV CLOSE
0.0380
HIGH
0.0389
LOW
0.0385
VOLUME
33.35K
TURNOVER
--
52 WEEK HIGH
0.1800
52 WEEK LOW
0.0205
MARKET CAP
--
P/E (TTM)
-0.0139
1D
5D
1M
3M
1Y
5Y
1D
SAB Biotherapeutics Names David Zaccardelli as Board Chair and Rita Jain as Director
Reuters · 8h ago
SAB BIOTHERAPEUTICS INC - DAVID ZACCARDELLI APPOINTED AS CHAIR OF SAB BIO BOARD
Reuters · 8h ago
U.S. RESEARCH ROUNDUP-Alphabet, Hershey, Micron Technology
Reuters · 13h ago
Weekly Report: what happened at SABSW last week (1229-0102)?
Weekly Report · 2d ago
SAB BIOTHERAPEUTICS INC - AT THE MARKET OFFERING UP TO $75 MLN OF COMMON STOCK - SEC FILING
Reuters · 12/30/2025 15:10
SAB BIOTHERAPEUTICS INC - ENTERS SALES AGREEMENT WITH UBS SECURITIES - SEC FILING
Reuters · 12/29/2025 21:01
SAB BIOTHERAPEUTICS INC - CO MAY OFFER AND SELL FROM TIME TO TIME COMMON STOCK OF UP TO $75 MLN - SEC FILING
Reuters · 12/29/2025 21:01
Weekly Report: what happened at SABSW last week (1222-1226)?
Weekly Report · 12/29/2025 09:53
More
About SABSW
SAB Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of human polyclonal immunotherapeutic antibodies, or human immunoglobulin G (hIgG), to address immunology disorders. The Company is focused on developing product candidates for disease targets where a differentiated approach has the greatest potential to be either first-in-class against novel targets or best-in-class against complex targets to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders. The Company’s lead product candidate, SAB-142, is a human anti-thymocyte globulin (ATG) focused on preventing or delaying the progression of T1D. SAB-142 is expected to reduce autoimmune beta cell destruction and delay progression or onset of T1D in patients with Stage III or Stage II T1D. The Company’s genetic engineering platform produces human, multi-targeted, high-potency immunoglobulins, without the need for human donors or convalescent plasma.

Webull offers SAB Biotherapeutics Inc stock information, including NASDAQ: SABSW real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SABSW stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SABSW stock methods without spending real money on the virtual paper trading platform.